Viridian Therapeutics, Inc.
VRDN
$18.84
$0.81754.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.90% | 4.86% | -3.82% | -12.97% | -80.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.90% | 4.86% | -3.82% | -12.97% | -80.41% |
| Cost of Revenue | 48.51% | 76.02% | 40.31% | 136.44% | 91.46% |
| Gross Profit | -48.56% | -76.14% | -40.38% | -136.99% | -93.66% |
| SG&A Expenses | -20.81% | -28.38% | -35.70% | 9.23% | 42.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.12% | 41.63% | 17.50% | 21.93% | 18.39% |
| Operating Income | -48.17% | -41.67% | -17.52% | -21.98% | -19.08% |
| Income Before Tax | -50.87% | -41.35% | -13.55% | -18.66% | -15.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.87% | -41.35% | -13.55% | -18.66% | -15.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.87% | -41.35% | -13.55% | -18.66% | -15.24% |
| EBIT | -48.17% | -41.67% | -17.52% | -21.98% | -19.08% |
| EBITDA | -48.31% | -41.79% | -17.55% | -21.98% | -19.03% |
| EPS Basic | -28.18% | 0.41% | 32.29% | 49.02% | 47.84% |
| Normalized Basic EPS | -4.79% | 5.96% | 25.57% | 15.49% | 12.78% |
| EPS Diluted | -28.18% | 0.41% | 32.29% | 49.02% | 47.84% |
| Normalized Diluted EPS | -4.79% | 5.96% | 25.57% | 15.49% | 12.78% |
| Average Basic Shares Outstanding | 41.74% | 47.54% | 51.78% | 42.05% | 36.62% |
| Average Diluted Shares Outstanding | 41.74% | 47.54% | 51.78% | 42.05% | 36.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |